Paul Rubinstein

Malignant heme #lymphoma doc #taking care of persons living with HIV and Cancer

[amfAR @amfAR]

Breaking news from #CROI2025: Two probable HIV cures, the Chicago and Oslo Patients, were announced. If confirmed, the total number of known cures will rise to 10. Read article: https://t.co/Uabz20ow3s

[University of Illinois Cancer Center @UICancerCenter]

At #CROI2025, our physician researcher @PaulRubinstein4 of @thisisuic @UIHealth presented findings from Chicago Patient (8th person living w/ HIV in remission off #ART after CCR5d32/d32 allogeneic stem cell transplant). @NIAIDNews,#NIAIDVRC,@theNCI & @CookCtyHealth collab vital.

[UIC Heme Onc Fellowship @UIC_HO_Fellows]

Poster presentation at @asco #GU25 by our fellow Dr. Michael Weinfeld looking at low-dose abiraterone adherence/cost vs standard dose abiraterone 💊

[UIC Heme Onc Fellowship @UIC_HO_Fellows]

Congrats to our all ⭐️ graduating fellows!!
Dr. Kevin Prescott
Dr. Ana Maria Avila
Dr. Lucas Maahs
We are so excited for what the future holds for you all!
@UICancerCenter

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH23 | Franck Morschhauser, University of Lille, presents a post-hoc analysis of the POLARIX study on the prevalence & clinical outcomes of molecularly defined subtypes of DLBCL. N=594, high-risk DHL/THL patients with DZsigPos DLBCL may benefit from Pola-R-CHP vs R-CHOP. According to LymphGen classification, EZB, MCD, and unidentified subtypes may benefit from Pola-R-CHP. #lymphoma #lymsm #leusm

[Paul Rubinstein @PaulRubinstein4]

@sheeba_baaqeel @RoswellHemOnc @RoswellPark We are all proud of you Dr. Ba Aqeel

[UIC Heme Onc Fellowship @UIC_HO_Fellows]

Some of our 3rd year fellows Dr. Maahs & Dr. Avila presenting their research @ASH_hematology #ASH23 🩸 @UICancerCenter

[Muhammad Junaid Tariq @MuhammadJTariq]

#ASH23 Thank you to my amazing mentors @Matt_Cortese @Francis77605164 @PaulRubinstein4 and colleagues for visiting my poster and show support! @RoswellHemOnc #lymsm

[Graham Collins @graham74GC]

Rutherford et al - BV-AVD v N-AVD in older Hodgkin
- SWOG 1836 study, 60y+, n=103 (approx 50 each arm)
- med age 66, more high risk in N-AVD
- Less tox with N-AVD: GI, PN, sepsis
- 1y PFS 64v93%
- 1y OS 83v95% (not stat signif)
- NRM 4v14%
A game changer. #ASH23 #lymsm

[Raul Cordoba, MD, PhD #EHA2026 @DrRaulCordoba]

N-AVD vs BV-AVD in older patients with #Hodgkin #lymphoma. No words needed. To me, the new SoC #lymsm #ASH23

[Irum Khan @Irumkhan_hem]

A prospective approach linking individual level pt reported SDOH data to early adverse AML outcomes. Proud of @EshanaShahMD for an excellent oral abstract and the dedicated efforts of leukemia teams, trainees and patients @UICancerCenter and @LurieCancer

[ACS Journal Cancer @JournalCancer]

New! Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study

https://t.co/zTOxjJKBmK

@oncoalert @jasonlukemd @AMC_Studies

[AMC POSEC Social @AMC_Studies]

Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study - Rajdev - Cancer - Wiley Online Library https://t.co/uZ5s7T0geD

[Karen Sweiss @KarenSweiss]

Art of Oncology Special Edition ... honoring the personal stories that have touched our ❤️ and made us cry. I still go back to many of these and read them. We should take pauses in our busy lives and reflect on how humbling it is to treat cancer https://t.co/MSAlvxvZaM

[Joe Ziegelbauer @DrJZ_]

I'm excited to share that our new paper is published. Many thanks to our wonderful team that made this possible. We are also grateful to the clinical trial participants for their contributions. #kshv #hhv8 #RNAseq #herpes #virus #OpenAccess https://t.co/QdeYby7Dcc

[Barbara Pro @bpromd]

How I Treat Post-Transplant Lymphoproliferative Disorder https://t.co/OZGX2MpXSw @jenamengual @columbiacancer @nyphospital

[Maarten van Smeden @MaartenvSmeden]

It is the only way

[Paul Rubinstein @PaulRubinstein4]

the best plate ever, though this hiv lymphoma doc is biased

[Vinay Prasad MD MPH @VPrasadMDMPH]

Guess the persons job

[Karine Tawagi MD @DrKarineTawagi]

Out today in collaboration with @asco, Dr. Reizine & I discuss why exercise is important for patients with prostate cancer, common challenges & types of exercises that may be helpful! 🏃‍♂️🚴🏽 🧘‍♂️ 🏋🏽‍♀️ #prostatecancer #guonc

https://t.co/F4Ky1GIy0L

[Kate Lurain @DrKateLurain]

Excited to see the important results of BV-AVD in HIV+ Hodgkin lymphoma in print!

2-yr PFS 87% and OS 92% plus increases CD4/CD8 counts. Great work by Paul Rubinstein and @AMC_Studies

https://t.co/pGfjG0cvO6